NCT06047379 2026-03-02Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.Phase 1/2 Recruiting134 enrolled
NCT03452774 2025-10-28SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryMassive Bio, Inc.Recruiting50,000 enrolled
NCT04543188 2025-10-23A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementPfizerPhase 1 Terminated65 enrolled 52 charts
NCT04521686 2025-06-27Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT01386580 2015-01-22An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.BBB-Therapeutics B.V.Phase 1/2 Completed84 enrolled
NCT00006368 2013-05-01Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerNovartisPhase 1 Completed60 enrolled